These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Continuous-infusion high dose ifosfamide as salvage treatment for pre-treated soft tissue sarcoma].
    Author: Chen LK, Xu GC, Teng XY, Liang Y, Liu JL, Zhou XM.
    Journal: Ai Zheng; 2002 Aug; 21(8):903-6. PubMed ID: 12478904.
    Abstract:
    BACKGROUND & OBJECTIVE: Adriamycin, dacarbazine and ifosfamide are three effective chemotherapy drugs in treating progressive soft tissue sarcoma. However, few regimen is effective for the patients who failed in treatment with prior Adriamycin and ifosfamide at standard dose. This study was designed to observe and evaluate the efficacy and toxicity of high dose ifosfamide(HDI) regimen on pre-treated soft tissue sarcoma. METHODS: Ten patients with advanced soft tissue sarcoma and 5 patients after surgical resection were treated with HDI administered by continuous infusion at a dose of 14 g/m2 per cycle over 6 days. All patients were pretreated with anthracycline +/- standard dose ifosfamide. RESULTS: An overall response rate of 40% was observed with 2 complete and 2 partial remission. In the follow up at 4-48 month, the overall median survival time was 21 +/- 3.29 months and the median response duration was 6 +/- 1.45 months. The major toxicity was myelosuppression. 45.9% patients experienced grade 3-4 neutropenia. CONCLUSION: HDI is an active salvage regimen in anthracycline +/- standard dose ifosfamide pretreated soft tissue sarcoma.
    [Abstract] [Full Text] [Related] [New Search]